Side-by-side · Research reference
CagrilintidevsHGH 191AA
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 3HUMAN-REVIEWED35/64 cited
BFDA-ApprovedHUMAN-REVIEWED0/75 cited
HGH 191AA
Recombinant hGH · FDA-Approved
0.024–0.034 mg/kg/dayPediatric GHD dose
2–4 hoursPlasma half-life
191 AASequence length
SQ · Daily · Evening preferred
01Mechanism of Action
Parameter
Cagrilintide
HGH 191AA
Primary target
Amylin receptor (AMYR) and calcitonin receptor (CTR) heterodimeric complexesBailey 2026
Growth hormone receptor (GHR) — JAK2/STAT5 pathway
Pathway
AMYR/CTR agonism → Central satiety signaling → Reduced food intake, delayed gastric emptying, suppressed glucagonBailey 2026
GHR activation → JAK2/STAT5 → liver IGF-1 synthesis + direct metabolic effects
Downstream effect
Central satiety induction, prandial glucagon suppression, reduced caloric intake, weight loss, improved glycemic controlBailey 2026Yamauchi 2026
Linear growth, lipolysis, protein synthesis, nitrogen retention, carbohydrate metabolism modulation
Feedback intact?
Yes — acts via physiological amylin pathways
No — exogenous GH bypasses hypothalamic-pituitary axis, suppresses endogenous pulsatility
Origin
Second-generation non-aggregating long-acting amylin analogue designed for once-weekly dosingBailey 2026
Recombinant DNA technology — 191 AA, identical to pituitary hGH, no methionyl residue
Antibody development
—
Rare — <2% develop binding antibodies, typically non-neutralizing
02Dosage Protocols
Parameter
Cagrilintide
HGH 191AA
Standard dose (combination)
Cagrilintide 2.4 mg + Semaglutide 2.4 mg (CagriSema)Yamauchi 2026
Phase 3 REDEFINE 5 trial dosing.
—
Monotherapy dosing
Dose-dependent, under investigation
Monotherapy trials reported in meta-analysis.
—
Frequency
Once weekly (subcutaneous)Bailey 2026
Long-acting formulation.
Once daily, typically evening
Evening administration mimics physiological GH pulse.
Evidence basis
Phase 3 RCT (REDEFINE 5), meta-analysis of 3 RCTs (n=3545)Yamauchi 2026Ahmed 2026
FDA-approved / decades of RCT data
Duration
26–52 weeks in trialsYamauchi 2026
Years (children until epiphyseal closure); indefinite (adult GHD)
Pediatric GHD
—
0.024–0.034 mg/kg/day SQ
6–7× per week dosing typical. Brand-specific ranges.
Adult GHD
—
0.004–0.016 mg/kg/day SQ
Start low, titrate based on IGF-1 levels.
Turner syndrome
—
0.045–0.050 mg/kg/day SQ
Idiopathic short stature
—
0.037 mg/kg/day SQ
AIDS wasting
—
0.1 mg/kg/day SQ (high-dose)
Short-term indication. Monitor glucose.
Monitoring
—
IGF-1, glucose, thyroid function, bone age (children)
03Metabolic / Fat Loss Evidence
Parameter
Cagrilintide
HGH 191AA
Weight loss vs semaglutide
7.47% greater percentage weight lossAhmed 2026
CagriSema combination vs semaglutide monotherapy (meta-analysis).
—
Absolute weight change
Significantly greater absolute weight reductionAhmed 2026
Mean difference favoring combination therapy.
—
Mechanism
Central satiety inductionBailey 2026
Lipolysis via hormone-sensitive lipase activation, FFA oxidation
Glycemic benefit
Reduced fasting glucose and HbA1cAhmed 2026
Synergistic effect with semaglutide in combination.
—
Body composition
Predominant fat loss with weight reduction
↓ fat mass, ↑ lean mass, ↑ bone mineral density (children)
Mitochondrial function
In vitro effects on skeletal muscle mitochondria under metabolic stress conditionsOld 2026
C2C12 myotube study; clinical relevance under investigation.
—
Key publications
REDEFINE 5 (Yamauchi 2026) · Ahmed meta-analysis 2026 · Bailey review 2026Yamauchi 2026Ahmed 2026Bailey 2026
—
Primary fat target
—
Visceral and subcutaneous adipose tissue
Effect on lean mass
—
Significant lean mass increase (protein synthesis, nitrogen retention)
Insulin sensitivity
—
Acute insulin resistance (anti-insulin effect); chronic neutral-to-improved via fat loss
IGF-1 elevation
—
Dose-dependent, significant — primary anabolic mediator
Glucose metabolism
—
Hyperglycemia risk, especially high doses (AIDS wasting)
Clinical context
—
FDA-approved for AIDS wasting (cachexia). Off-label use for body recomposition lacks long-term safety data.
04Side Effects & Safety
Parameter
Cagrilintide
HGH 191AA
Gastrointestinal
Nausea, diarrhea (common with incretin-based therapies)Pardali 2026
Dietary management and nutritional monitoring recommended.
—
Injection site reactions
Local reactions possible with subcutaneous administration
—
Safety profile
Generally consistent with incretin-based therapies
Phase 3 and meta-analysis safety data.
—
Tolerability
Tolerability considerations similar to GLP-1RAs
—
Muscle preservation
Lean mass considerations during weight loss
In vitro mitochondrial effects observed; clinical impact under investigation.
—
Injection site reaction
—
Lipohypertrophy, lipoatrophy, erythema (rotate sites)
Fluid retention / Edema
—
Peripheral edema, arthralgia, carpal tunnel syndrome (dose-dependent)
Glucose intolerance
—
Hyperglycemia, new-onset diabetes (anti-insulin effect)
Intracranial hypertension
—
Benign intracranial hypertension (pseudotumor cerebri) — headache, visual changes, papilledema
Slipped capital femoral epiphysis
—
SCFE risk in children — limp, hip/knee pain (requires surgery)
Scoliosis progression
—
Rapid growth may unmask/progress scoliosis (monitor spine in children)
Hypothyroidism
—
Central hypothyroidism unmasking or worsening (monitor TSH, free T4)
Cancer risk
—
Contraindicated in active malignancy. Theoretical risk in cancer survivors (controversial).
Antibody formation
—
Rare (<2%), typically non-neutralizing. Loss of efficacy if neutralizing antibodies develop.
Pancreatitis
—
Rare. Higher risk in children with certain syndromes (Prader-Willi).
Gynecomastia
—
Adolescent males (physiological during puberty, may be exacerbated)
Absolute Contraindications
Cagrilintide
- ·Hypersensitivity to cagrilintide or formulation components
HGH 191AA
- ·Active malignancy or history of cancer (especially childhood cancer survivors with risk factors)
- ·Acute critical illness (post-cardiac surgery, trauma, acute respiratory failure)
- ·Diabetic retinopathy (active proliferative or severe non-proliferative)
- ·Prader-Willi syndrome with severe obesity, sleep apnea, or respiratory impairment
- ·Closed epiphyses (for growth indications)
Relative Contraindications
Cagrilintide
- ·Severe gastrointestinal disease
- ·History of pancreatitis (incretin-based therapy consideration)
HGH 191AA
- ·Diabetes mellitus (monitor closely, may require insulin adjustment)
- ·Intracranial lesions or history of intracranial hypertension
- ·Scoliosis (monitor curve progression)
- ·Untreated hypothyroidism (treat before GH initiation)
- ·Severe obesity (assess OSA risk, cardiovascular status)
05Administration Protocol
Parameter
Cagrilintide
HGH 191AA
1. Dosing frequency
Once-weekly subcutaneous injection. Long-acting formulation designed for weekly administration schedule.Bailey 2026
Add diluent (sterile water or bacteriostatic water per manufacturer) to vial. Swirl gently — do not shake. Solution should be clear, colorless. Concentration varies by brand (e.g., 5 mg or 10 mg per vial).
2. Combination form
Co-formulated with semaglutide as CagriSema for single weekly injection combining amylin and GLP-1 receptor agonism.Yamauchi 2026Bailey 2026
Subcutaneous — rotate sites: abdomen, thigh, buttocks, upper arm. Avoid same site within 1 cm for 2 weeks to prevent lipodystrophy.
3. Injection site
Subcutaneous — typically abdomen, thigh, or upper arm. Rotate injection sites weekly to minimize local reactions.
Once daily, evening preferred (6–8 PM or pre-sleep). Mimics physiological nocturnal GH secretion. Consistency is critical.
4. Storage
Refrigerate 2–8°C. Follow product-specific storage instructions for pre-filled pens or vials. Protect from light.
Unreconstituted: refrigerate 2–8 °C, protect from light. Reconstituted: refrigerate, use within 14–28 days (brand-specific). Do not freeze.
5. Dietary considerations
Nutritional monitoring recommended during treatment. Dietary management strategies important for tolerability and outcomes.Pardali 2026
27–31G, 4–8 mm insulin syringe or pen device. Pinch skin, 45–90° angle depending on subcutaneous thickness.
6. Monitoring
—
Baseline and periodic: IGF-1 (target age/sex-adjusted midrange), fasting glucose, HbA1c, thyroid function (TSH, free T4), bone age (children), lipid panel. Fundoscopy if headache/visual symptoms.
06Stack Synergy
Cagrilintide
+ Semaglutide
StrongCagrilintide (amylin receptor agonist) and semaglutide (GLP-1 receptor agonist) act on distinct receptor systems to produce synergistic weight loss through complementary mechanisms — central satiety via amylin pathways plus incretin-mediated glucose control and appetite suppression via GLP-1. Co-formulated as CagriSema, this combination demonstrates 7.5% greater weight loss versus semaglutide monotherapy in Phase 3 trials with additional benefits on glycemic control and lipid parameters.
- CagriSema
- Cagrilintide 2.4 mg + Semaglutide 2.4 mg
- Frequency
- Once weekly subcutaneous
- Duration
- 26–52 weeks (trial data)
- Primary benefit
- Enhanced weight loss, improved glycemic control, multi-pathway metabolic modulation
HGH 191AA
+ Ipamorelin
ModerateIpamorelin (GHRP) stimulates endogenous GH release, which is redundant when exogenous rhGH is administered. However, ipamorelin may still amplify pulsatility of remaining endogenous secretion in partial GHD or during GH dose titration. Not typically combined in standard clinical practice; more common in experimental or off-label protocols. Limited evidence for additive benefit.
- HGH 191AA
- Standard dose per indication
- Ipamorelin
- 100–200 mcg SQ · morning (if used)
- Note
- Monitor IGF-1 closely; avoid supraphysiological levels
- Primary benefit
- Theoretical enhancement of pulsatility; limited clinical rationale
+ Tesamorelin
WeakTesamorelin (GHRH analogue) stimulates endogenous GH secretion, which is unnecessary when exogenous rhGH is already provided. Combining both offers no mechanistic advantage and increases cost, side effects, and IGF-1 elevation risk. Not recommended in clinical practice.
- Note
- Combination not recommended — choose one GH modality
- Primary benefit
- None — redundant mechanisms